By Jonathan Stempel NEW YORK, Feb 10 (Reuters) - Pfizer agreed to accept $29 million to resolve a dispute with the U.S.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

The stock has been fairly stable over the past year.

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.